Author: Jesse Landry

There’s something quietly lethal about a startup that shows up in a legacy industry with tech that doesn’t just improve outcomes, it dares to challenge the entire method of treatment. Liquet Medical isn’t here to impress the crowd with noise. They’re too busy building a future where blood clots in the lungs get the kind of real-time, precision-guided therapy that feels more NASA than 1990s medical protocol. Co-founders John Schindler and Derek Hall didn’t come into this with a pitch deck and a dream. They came with decades of trench work, John with 30+ years of hard-won experience across Atrium…

Cardiac ablation isn’t exactly a dinner party topic, unless you’re Field Medical, and your idea of a party is electrifying the heart (literally) with a tech platform that reimagines how we treat the most stubborn rhythm disorders out there. On July 1st, the team at Field Medical dropped a Series B round that landed like a controlled thunderclap, $35 million, co-led by BioStar Capital and Cue Growth, with strong follow-through from existing strategic investors. Not a fluke. Not luck. It’s what happens when you build something with surgical precision and real-world urgency, and back it with a track record that…

In a world where B2B buyers dodge sales calls like spam filters on caffeine, trust has quietly become the most valuable currency in the enterprise game. And while most vendors are still handing out PDFs like it’s 2010, Deeto is over here turning real customer voices into liquid gold. Not testimonials. Not logos. Proof. At scale. With teeth. Founded in 2022 and based in NYC, Deeto was born from a hard truth: B2B relationships got transactional, robotic, and frankly… boring. Buyers research quietly, delay vendor interaction, and trust peers over pitch decks. So Co-Founders Eran Baron (CEO), Golan Raz (COO),…

The construction site always had two constants: dirt and delays. Surveying crews pacing across sun-scorched job sites with tripods and tape measures, burning time and budget like it’s a rite of passage. But time doesn’t forgive inefficiency, and neither does capital. Enter Civ Robotics, where precision meets hustle, and the dirt finally gets some brains. Founded in 2018 by Tom Yeshurun and Liav Muler, Civ Robotics was born from frustration, the best kind of fuel in tech. Tom, an ex-IDF ground forces officer and civil engineer, watched $5 million evaporate on layout work that was riddled with human error. That…

Some biotech stories are born in the clouds of academia and die in the fog of regulatory indecision. But every now and then, a company drops with the weight of something real, science with teeth, a market with hunger, and leadership that knows exactly what to do with both. Syntis Bio isn’t just here to play. They’re here to digest the market. Founded in 2022 out of MIT’s Langer and Traverso labs, Syntis Bio started with a very Gatesian mission, figure out how to deliver oral meds more effectively for kids in low-resource settings. That problem cracked open a much…

Emerald AI just dropped $24.5M of pure voltage into the grid. And no, this isn’t just another AI startup pitching latency metrics and buzzword yoga. This is the company making America’s AI obsession actually work, by keeping the lights on. Launched today out of Washington, DC, Emerald AI is solving the kind of billion-dollar bottleneck most people don’t even know exists, the grid can’t keep up with the appetite of modern AI. We’re talking about data centers demanding 50 to 100 gigawatts of power by 2030, enough to light up entire countries, and grid queues that look more like retirement…

Wisq just raised the bar with a $15 million in a Series extension round, backed again by the trusted trio, Norwest Venture Partners, Shasta Ventures, and True Ventures. That’s not just capital, it’s conviction. Same investors, double down. That doesn’t happen unless you’ve built something smarter than the market expects and faster than your competitors can imitate. And Wisq, founded in 2021, has done exactly that, migrating from social graphs to HR graphs with the kind of pivot that doesn’t just make headlines, it makes incumbents nervous. Let’s talk about why this one matters. Jim Barnett, Goutham Kurra, and Chih-Po…

In the world of biotech, we’ve seen stem cells pitched as everything from a medical miracle to a Silicon Valley spa treatment, but what Gallant Therapeutics just pulled off? That’s not hype. That’s precision. $18 million in fresh Series B fuel, led by Digitalis Ventures with returning conviction from BOLD Capital Partners and Hill Creek Partners, plus a serious nod from new investor NovaQuest Capital Management, says one thing loud and clear: regenerativemedicine for pets just got a real contender. Let’s not gloss over it. Gallant isn’t slinging snake oil or repackaging yesterday’s science in tomorrow’s bottle. This San Diego-based…

Campfire just lit up the ERP scene with a $35 million Series A round, and this isn’t your dad’s enterprise software story. This is what happens when someone who’s been inside the machine decides to build a better one. That someone is John Glasgow, a finance vet who lived the chaos of legacy systems at Adobe, Invoice2go, and Bill.com, then did what most don’t, burned the manual and built a product that actually understands the people using it. ERP has long been a synonym for slow, stiff, and siloed. Midmarket companies outgrowing QuickBooks were forced into SAP and NetSuite, two…

Just under the surface of most enterprise tech stacks lies a goldmine of data, untapped, underleveraged, and aging faster than an inbox full of unread Slack notifications. The difference between surviving and dominating in 2025? Knowing how to turn that data into foresight, not just hindsight. Enter CRED, and no, it’s not just another AI company playing Mad Libs with buzzwords. This one came to play offense. After quietly building in the shadows since 2018, CRED just stepped into the light with a $15M seed round led by defy.vc, backed by heavyweights like HOF Capital, Alumni Ventures, LDV Partners, Streamlined…